Therapies directed against receptor tyrosine kinases are effective in many cancer subtypes, including lung and breast cancer. We used a phosphoproteomic platform to identify active receptor tyrosine kinases that might represent therapeutic targets in a panel of 25 melanoma cell strains.
Introduction
Next generation cancer therapies that target receptor tyrosine kinases (RTK) have a major impact on the disease-free progression and survival of patients with breast cancer and non-small cell lung carcinoma (NSCLC). RTK inhibitors in clinical use include the antibodies trastuzumab for HER2-positive breast cancer and cetuximab in epidermal growth factor receptor (EGFR)-positive colorectal cancer. Small molecule kinase inhibitors also target EGFR in NSCLC (Erlotinib), and KIT or platelet-derived growth factor receptor (PDGFR) in gastrointestinal stromal tumors (Imatinib).
The incidence of melanoma has steadily risen in the United States over the past 30 years, yet individuals with late-stage melanoma have a median survival time of only 9 months (1-3). Imatinib has been used to treat melanomas with mutationally activated KIT, whereas experimental studies show that targeting RTKs such as MET and insulin-like growth factor 1 receptor (IGF1R) may inhibit melanoma cell proliferation and survival (4) (5) (6) (7) (8) (9) . The use of RTK-directed therapeutics in melanoma has, however, been limited by the lack of available information about active RTKs in this disease.
To identify potential RTK therapeutic targets in melanoma, we surveyed the expression of all 58 human RTKs and their agonists in a panel of 24 low-passage melanoma cell strains and 1 commercially available melanoma cell line. The functional activation of 42 human RTKs was also examined and used to identify which RTKs are most frequently and intensely activated in melanoma. Short hairpin RNA (shRNA)-mediated knockdown of AXL, HER3, and IGF1R, 3 of the RTKs identified in the screen, resulted in decreased melanoma cell proliferation. AXL knockdown also reduced melanoma cell migration and these cellular responses seem to be regulated by the STAT3 signaling pathway. These data identify new candidates for therapeutic intervention in melanoma.
Materials and Methods

Cell culture
Yale University (YU)-designated and WW165 melanoma cell strains were derived from primary and metastatic lesions as described (10) . Melanoma tumors were excised as part of patient clinical care and were collected with the participants' informed written consent according to HIPAA (Health Insurance Portability and Accountability Act) regulations with the approval of the Yale Human Investigation Committee. Primary and metastatic melanoma cell strains were used prior to passage 20. Most melanoma cells were cultured in OptiMEM (Invitrogen) supplemented with 5% FBS and 1% penicillin/streptomycin (basal medium). The WW165 primary melanoma and YUHEIK mucosal melanoma cells were grown in basal medium supplemented with 0.1 mmol/L IBMX (3-isobutyl-1-methylxanthine; Sigma-Aldrich). Normal human melanocytes from newborn foreskins (NBMEL) and discarded adult skin (RMP32F) were grown in basal medium supplemented with 16 nmol/L 12-O-tetradecanoyl phorbol-13-acetate, 0.1 mmol/L 3-isobutyl-1-methylxanthine, 2.5 nmol/L cholera toxin, 1 mmol/L Na 3 VO 4 , and 0.1 mmol/L N6,2 0 -Odibutyryladenosine 3 0 ,5 0 -cyclic monophosphate (SigmaAldrich), termed TICVA (11) . HEK293T cells from the American Type Culture Collection (ATCC) were grown in Dulbecco's modified Eagle's medium containing 10% FBS, 1% penicillin/streptomycin, and 1% HEPES. MDA-MB-231 cells, MDA-MB-453 cells, and BT474 cells (ATCC) were grown in RPMI containing 10% FBS and 1% penicillin/streptomycin. iScript cDNA Synthesis Kit from BioRad by using 0.8 mg of RNA per reaction. Universal TaqMan Master Mix (Applied Biosystems) was used to conduct quantitative real-time PCR (qRT-PCR) by using a 1 to 10 dilution of the resulting cDNA. The following primers were used following the manufacturer's protocols: AXL (Hs0024357_m1), HER3 (Hs00951455_m1), and glyceraldehyde 3 phosphate dehydrogenase (GAPDH; Hs99999905_m1; Applied Biosystems). Relative mRNA expression was determined with the DCt method by using GAPDH as the reference gene. Gene expression values for tumor RNAs were normalized to a negative control. A single RNA preparation was analyzed for each microdissected tumor, and duplicates for each tumor block.
Cell lysis, RTK arrays, immunoblotting, and hierarchical clustering
Where indicated, cells were starved in 0.1% serum prior to lysis, and pervanadate (50 mmol/L final) was added for 20 minutes before lysis. Cells were lysed in NP-40 lysis buffer [1% NP-40, 150 mmol/L NaCl, 50 mmol/L Tris (pH 7.4), 5 mmol/L EDTA, 10% glycerol with complete EDTA-free protease inhibitor tablets (Roche) and phosphatase inhibitor cocktails 1 and 2 (Sigma-Aldrich) added immediately before cell lysis]. Cell lysates (250 mg) were analyzed with the Human Phospho-RTK Array Kit (R&D Systems); array maps at http://www.rndsystems.com/pdf/ary001.pdf. Protein samples were prepared for electrophoresis by addition of 5Â Laemmli sample buffer, and immunoblotting was carried out on nitrocellulose membranes blocked in 5% milk in Tris-buffered saline Tween-20 (1.5 mol/L NaCl, 0.2 mol/L Tris-HCl, 0.05% Tween 20) . Membranes were incubated with antibodies in 5% milk or 5% bovine serum albumin overnight at 4 C: anti-pHER3, anti-pIGF1R, anti-IGF1R, anti-pKIT, anti-MERTK, anti-pMET, anti-MET, antipSTAT3, anti-STAT3, anti-pAKT, anti-AKT (Cell Signaling Technology), anti-HER3, anti-GAPDH (Santa Cruz Biotechnology), anti-TYRO3 (Abcam), and anti-KIT (Dako). Secondary antibodies conjugated to horseradish peroxidase were used at a 1:10,000 dilution for 1 hour at room temperature prior to development (Thermo Scientific).
Nonsupervised hierarchical clustering was done by manually determined phospho-array data values ranging from 0 (background) to 5 (maximum phosphorylation; Tables 1  and 2 ). Clustering of RTK data was done by Pearson's correlation with complete linkage along sample and protein dimensions.
Immunoprecipitation
HER3 immunoprecipitation (IP) was done with 1 mg protein and 800 ng HER3 antibody sc-7390 (Santa Cruz); KIT IP with 300 mg protein and 1 mg A4502 (Dako); MET IP with 550 mg protein and 1mg MET antibody sc-10 (Santa Cruz); IGF1R IP with 500 mg protein and 100 ng antibody 3027 (Cell Signaling Technology) at 4 C overnight. Then, 12 mL of a 50% slurry of protein A/G beads (Thermo Scientific) was added to each IP for 1 hour. Beads were washed twice with NP-40 lysis buffer and once with salt-Tris buffer (0.1 mol/L NaCl; 10 mmol/L Tris-HCl, pH 7.4), then incubated at 100 C for 8 minutes in 2.5Â Laemmli sample buffer.
shRNA and lentiviral infection shRNA targeting AXL [RHS3979-9568950, AXL 1 (14) and RHS3979-9568949, AXL 2), HER3 (RHS3979-9630819; Q61R  Q61R  Q61K  V600E  V600E  V600E  V600E  V600E  V600E  V600K  V600K  V600K   BT474  MB231  MB453  NBMEL  YUGOE  YUHEF  YUHEIK  YUHOIN  YUKIM  YUNIGE  YUPLA  YUROB  YUROL  YUSIV  YUZOR  YUCAS  YUTICA  YUDOSO  YUCOT  YUGEN8  YUHUY  YUSAC2  YUSIK  YUSTE  YUKSI  YULAC Cell proliferation Cells were plated in duplicate clear-bottom 96-well plates at a density of 1,000 cells per well in 100 mL of OptiMEM. Approximately 6 hours after plating, cells were incubated with lentivirus in OptiMEM containing 4 mg/mL polybrene for 20 hours. Immediately following infection, a T 0 time point was taken by incubating one plate with CellTiter-Glo, per the manufacturer's instructions (Promega). Relative cell Q61R  Q61R  Q61K  V600E  V600E  V600E  V600E  V600E  V600E  V600K  V600K   NBMEL  YUGOE  YUHEF  YUHEIK  YUHOIN  YUKIM  YUNIGE  YUPLA  YUROB  YUROL  YUSIV  YUZOR  YUCAS  YUTICA  YUDOSO  YUCOT  YUGEN8  YUHUY  YUSAC2  YUSIK  YUSTE  YUKSI NOTE: Summary of RTK activation in melanoma cell lines and newborn melanocytes scored as described in Table 1 . 
Cell migration
Cell lines were stably infected with scrambled shRNA or AXL shRNA and were seeded at 30,000 cells/well in 24-well plates with 8-mm filter inserts (BD Biosciences) in Opti-MEM with 0.1% FBS. OptiMEM with 5% FBS was used as a chemoattractant. Cell lines were analyzed in triplicate, with a representative graph chosen for each.
Results
Transcriptional profiling of melanoma cell lines
We used transcription profiling to identify RTKs commonly expressed in melanoma cell lines and in normal melanocytes. Of the 58 human RTK genes, 43 RTKs were transcribed above a conservatively chosen expression threshold in at least one melanocyte culture, and 53 RTKs were above the threshold in at least one melanoma cell line (Supplementary Tables S1 and S2 ). Some RTKs, including IGF1R, MET, and TYRO3, were highly expressed in most melanomas and normal melanocytes, whereas fibroblast growth receptor 2 (FGFR2), EGFR, and ROS1 were rarely, if ever, detected above the expression threshold in either melanoma cells or melanocytes. AXL and HER3 were expressed at higher levels in melanoma cells than in melanocytes, but KIT and MERTK expression was lower in melanoma cells compared with melanocytes (Supplementary Tables S1 and S2 ).
Survey of active RTKs in melanoma
Generally, the abundance of RTK mRNA does not predict functional activity; although RTKs such as HER2 and MET are frequently activated via gene amplification and overexpression, mutationally activated RTKs can be potent oncogenes when expressed at low levels (17) (18) . Because tyrosine (Tyr) phosphorylation is indicative of the signaling activity of RTKs (19), we surveyed receptor activation by using phospho-arrays that capture 42 RTKs from cell lysates and are probed with antiphosphotyrosine (anti-PTyr). To enhance the endogenous PTyr signals, cells were also analyzed after treatment with pervanadate, a tyrosine phosphatase inhibitor. Pervanadate treatment significantly enhanced the cell lysate signals seen on the phospho-RTK arrays, but did not greatly alter the pattern of RTK activation (Fig. 1A) . Phospho-array controls included breast cancer BT474 and MDA-MB-453 cells, which are known to express active HER2, and MDA-MB-231 cells, which express little or no active HER3, but have substantial amounts of AXL (Table 1; refs. [20] [21] [22] .
As expected, RTK mRNA levels were only loosely correlated with receptor activation. For instance, colonystimulating factor 1 receptor (CSF1R) mRNA levels were high in both melanoma cell lines and normal melanocytes, yet CSF1R was rarely phosphorylated (Tables 1 and 2;  Supplementary Tables S1 and S2 ). The same trend was also observed for EPHA2 in melanoma cell lines and FGFR1 in normal melanocytes. Of the 42 RTKs analyzed via phospho-arrays, IGF1R, HER3, and MET were frequently activated and transcribed above the expression threshold in melanoma cell lines. Phosphorylation of other RTKs was more variable in comparison with RNA expression, suggesting the importance of other modulators such as growth factors or active coreceptors. Pervanadate treatment generally increased the number of RTKs activated and expressed above the threshold (Supplementary Tables  S1 and S2) .
RTK activation patterns were variable, even among cell lines with BRAF and NRAS activating mutations. Such mutations occur in 44% and 12%, respectively, of the melanoma cultures analyzed in this report. Examples of array variability are found in pervanadate-treated NBMEL, which have higher levels of phosphorylated macrophage stimulating 1 protein receptor (MST1R) than melanoma cell lines YUHEIK and YULAC (Fig. 1B) . Similarly, YUHEIK cells showed more activated EGFR than either newborn melanocytes or YULAC cells, whereas YULAC cells had lower activation of KIT and higher activation of IGF1R (Fig. 1B) . Despite these differences, the insulin receptor family (IR, IGF1-R), EGFR family (especially EGFR and HER3), MET family (MET and RON), and TAM family (TYRO3, AXL, and MERTK) were commonly activated in melanoma cultures (Tables 1 and 2) . A ranking of receptor activation across all melanoma cell strains was determined by summing the phosphorylation intensities for each individual RTK (Supplementary  Table S3 ). Interestingly, the 15 RTKs with the highest overall activation included receptors that had not been previously reported to be active in melanoma, including TYRO3, AXL, MERTK, and EPHB2 (Supplementary  Table S3 ). RTKs such as EGFR, FGFR3, IR, IGF1R, and TYRO3 were frequently activated with and without pervanadate treatment whereas HER3, MET, and RON were more commonly detected after pervanadate treatment, perhaps reflecting faster turnover of phosphotyrosine by endogenous phosphatases (Tables 1 and 2 ). The frequency of detection of phosphorylated EGFR and TYRO3 decreased with pervanadate treatment, possibly indicating a biological change such as heterologous desensitization through activation of other RTKs.
In both pervanadate-treated and untreated cultures, it was common to find multiple phosphorylated RTKs (Tables 1  and 2 ). Nonsupervised clustering was used to evaluate possible co-associations (Supplementary Tables S4 and  S5 ). Without pervanadate, there was some co-association of IGF1R and TYRO3 phosphorylation, with a subgroup showing common activation with IR, FGFR3, and EPHB2 (Supplementary Table S4 ). With pervanadate treatment, activation of multiple RTKs across cell lines was more common (Supplementary Table S5 ). Recently, a related set of primary array data analyzing 15 separate melanoma lines was reported. This dataset identified active RTKs such as HER3, IGF1R, and TYRO3 in non-pervanadate-treated samples, but these results were not validated (23) .
Validation of array data
We focused on validating TYRO3, MERTK, AXL, HER3, MET, KIT, and IGF1R because they were either among the most common or most novel active RTKs identified and because they represent attractive cancer therapeutic targets (Fig. 1C and D) . With the immunoblotting reagents available, we were able to determine the abundance of TYRO3 and MERTK, but could not assess their phosphorylation status for comparison with the phospho-array data. Although high levels of phosphorylation in pervanadate-treated cells permitted analysis of total cell lysates, immunoprecipitated phosphorylated RTKs could also be detected in untreated cells. The pattern of receptor activation in the melanoma cell lines analyzed in Figure 1 did not vary substantially with pervanadate treatment (Fig. 1C and D) . We considered the immunoblots more accurate in the instances where the arrays did not correlate with the immunoblots. Hence, the RTK arrays provided a useful, but imprecise, indication of which RTKs are active in a given cell line.
RTK activation in melanoma
To identify receptors that might be activated through autocrine circuits or overexpression, we compared the phosphorylation levels determined by phospho-array analysis to the transcriptional levels of the RTKs and their respective ligands. In untreated cell lines, a few RTK phosphorylations correlated with ligand mRNA expression including FGFR3::FGF13, AXL::GAS6, and HER4 with assorted ligands (Supplementary Table S6 ). Similarly, in pervanadate-treated cells, moderate correlations were found between RTK phosphorylation and ligand expression for AXL::GAS6, EPHA2::EFNA3, and FGFR3::FGF13. In both datasets, receptor phosphorylation was moderately associated with RTK mRNA expression for AXL, whereas ERBB4 and EGFR also showed correlations in untreated cells and KIT mRNA expression was correlated with KIT activation in pervanadate-treated samples (Supplementary Table S6 ).
The small number of cases for which receptor phosphorylations were identified in association with high ligand expression represent candidates for autocrine loops. Here, the limited sensitivity of the RTK arrays coupled with the possible chronic downregulation of ligand-activated RTKs means that there may be many false-negatives. Additionally, elevated expression can move the designated RTK above phospho-array threshold for detection, which may skew the results of our screen. The co-associations of RTK phosphorylation with high receptor mRNA levels may, however, identify cases for which RTK overexpression contributes to receptor activation.
The strongest correlations were found in comparison of receptor and ligand mRNA expression levels. For a subset of RTK/ligand pairs, including FGFR3 with several of its ligands, PDGFRb::PDGFb, AXL::GAS6, and ERBB4::neuregulin 3 (NRG3) NRG3, there were strong associations of mRNA levels (Supplementary Table S6 ). These RTK/ligand pairs represent candidates for autocrine activation, although for some pairs subcellular compartmentalization or the need for proteolytic activation of prohormones may limit RTK activity.
RTK knockdown influences melanoma cell proliferation, migration, and signaling
The phospho-array survey identified IGF1R as active in most of the melanoma cell lines (Tables 1 and 2 ). Because cells were maintained in medium supplemented with serum, which is rich in ligand IGF1, we explored whether IGF1R phosphorylation was affected by serum concentration. Three melanoma cell lines were serum-starved for a period of 24 to 48 hours and immunoblotting was used to measure the presence of total and phosphorylated IGF1R (Fig. 2A) . The persistence of IGF1R phosphorylation indicates that serum IGF1 is not the primary factor influencing IGF1R activation.
The high prevalence of IGF1R activation in our panel of melanoma cell lines suggested that it might be functionally important. Four melanoma cell lines characterized by phosphorylated IGF1R were infected with empty vector (pLKO), scrambled shRNA (SC), or shRNA against IGF1R (Tables 1 and 2; Fig. 2B ). IGF1R knockdown corresponded with decreased cell proliferation and a reduction in AKT signaling, in accordance with earlier studies (ref. 6 ; Fig. 2B and C).
AXL and HER3 were selected for further validation of the data generated by the phospho-array screen. We focused on these 2 receptors because they are relatively unexamined in the context of melanoma pathogenesis and because TAM family members are poorly characterized in cancers in general. Lentiviral vectors encoding shRNA directed against AXL or HER3 were used to knock down the respective receptors singly and in combination (Fig. 3A) . The growth of YURIF cells, which do not express AXL or HER3 (Tables 1 and 2 ; Fig. 1C and D) , was not affected by lentiviral-mediated knockdown of either RTK (Fig. 3B) . In contrast, knockdown of AXL or HER3 strongly inhibited (Fig. 3B) , which express active AXL and HER3 (Fig. 1C and D) . A milder reduction in proliferation was obtained by targeting active HER3 in YUROL cells (Tables 1 and 2; Fig. 3B ). YUKSI cells, which express AXL but have low AXL activity (Tables 1 and 2 ; Figs. 1C and D, and 3A) , displayed only slight reductions in proliferation and migration upon AXL knockdown (Fig. 3D and E). These alterations in proliferation and migration correlated with a slight reduction in phospho-STAT3 (Fig. 3A) . Knockdown of active AXL in YUSIV, YUSTE, and YUTICA melanoma cells evoked a more pronounced decrease in cell proliferation, cell migration, and STAT3 phosphorylation (Tables 1 and 2; Fig. 3A, D, and E) . Sporadic reductions in phospho-AKT were also observed on AXL knockdown (data not shown). Further validation of these effects was obtained by targeting AXL by using a second shRNA in 4 melanoma cell lines ( Supplementary  Fig. S1 ). These results support the biological relevance of AXL and HER3 in melanoma cells and substantiate the importance of targeting activated receptors.
Melanoma cell lines predict presence of RTKs in tumors
To verify that expression of the RTKs identified in our screen is not a cell culture artifact, snap-frozen tissues derived from the same original tumors were analyzed via qRT-PCR. AXL mRNA was identified by transcriptional profiling in YUDOSO, YUSIV, and YUSTE, but not in YUCOT melanoma cells (Table 3) . AXL mRNA and protein were variably detected in YULAC cells ( Fig. 1C  and D ; Table 3 ). qRT-PCR analysis of frozen tumor tissues revealed that YUDOSO, YUSIV, YUSTE, and YULAC tumors all express AXL, but the YUCOT tumor did not (Fig. 4A) . Similarly, HER3 mRNA was detected by transcriptional profiling of the YUCOT, YULAC, YUDOSO, YUSIV, and YUSTE melanoma cell strains as well as by qRT-PCR analysis of tissue from the corresponding tumors (Table 3 ; Fig. 4B ).
As expected, there was no direct correlation between the activity of an RTK in a cell line (Tables 1 and 2 ) and the presence of mRNA in the corresponding tumor ( Fig. 4A  and B) . Nonetheless, activated AXL and HER3 were only detected in melanoma cell lines for which the tumors expressed the corresponding receptors. The differences in rank expression of the RTKs in tumors versus cell lines may reflect tumor to cell strain differences, tumor heterogeneity, or differential infiltration by nontumor cells in the tumor microenvironment.
Discussion
We report here the first broad survey of functionally activated RTKs in a panel of early-passage melanoma cell strains. This survey represents one facet of an integrated analysis of a reference set of melanoma cell lines and corresponding tumor tissue that will eventually encompass transcription profiling, epigenetic analysis, copy number analysis, transcriptome and exome resequencing, and drug response profiling. We found that the insulin receptor family (IGF1R, IR), MET family (MET, MST1R), EGFR family (EGFR, HER3, HER4), and TAM family (TYRO3, AXL, MERTK) were commonly activated in melanoma (Tables 1 and 2). IGF1R was frequently and strongly activated in our panel of cell strains, and this activation did not seem to be serum-dependent (Tables 1 and 2 ; Fig. 2A) . A previous report showed that knockdown of IGF1R can greatly reduce melanoma cell growth and that targeting IGF1R reduced signaling through both the AKT and the mitogen-activated protein kinase pathways (6) . Our data also support the notion that knockdown of IGF1R may reduce cell growth in an AKT-dependent manner (Fig. 2) . Activation of IGF1R promotes liver metastases in uveal melanoma and activated IGF1R, along with activated HER3, is known to contribute to Herceptin resistance in breast cancer (24) (25) (26) (27) . Signaling through IGF1R also compensates for therapeutic inhibition of mTOR in breast and prostate cancer cells (28) . It is possible that activated IGF1R might serve an analogous role in melanoma and it will therefore be important to determine the mechanism of IGF1R activation in melanoma.
A recent study showed that HER4 may be somatically mutated in up to 19% of melanomas, and our survey reveals frequent activations of the EGFR family members in melanoma (29) . While this work was in progress, elevated HER3 expression and activation was reported in melanoma cells relative to normal melanocytes, with knockdown of HER3 reducing melanoma cell proliferation, migration, and invasion (30) (31) . Reduced HER3 expression was also correlated with reduced phospho-AKT and increased p27 expression (31) . The findings presented here are consistent with these reports, because our melanoma cell strains frequently show higher HER3 activation and mRNA than melanocytes (Tables 1 and 2; Supplementary Tables S1 and  S2 ) and because HER3 knockdown reduces melanoma cell proliferation (Fig. 3) . It has been proposed that activation of HER3 by NRG1 contributes to melanoma development and progression (30), but we did not identify a correlation between HER3 activation and the expression of ligands NRG1 or NRG2 (Supplementary Table S6 ). One explanation may be that NRG1 is important in early stages of melanoma but its expression does not persist in later stages; this is consistent with the reported higher frequency of activated HER3 in primary compared with metastatic melanomas (30) . The phospho-RTK array analysis also reveals coactivation of MET with EGFR family members such as HER3 (Tables 1 and 2 ). Because coordinate activation of MET with ERBBs often modulates resistance to EGFR inhibitors in NSCLC, combined inhibition of MET and ERBBs may be beneficial for a subset of melanomas as well (32) .
The TAM receptor family is well-studied in inflammation but is not yet completely characterized in carcinogenesis. Previous work shows that AXL mRNA is elevated in melanomas relative to normal melanocytes, in agreement with our transcriptional data (Supplementary Tables S1 and  S2; ref. 33) . Although TYRO3 and MERTK were reported to be preferentially expressed in melanomas, we found that TYRO3 is highly expressed in both melanocytes and melanomas and that MERTK expression is, on average, lower in melanoma cells compared with normal melanocytes (Supplementary Tables S1 and S2; refs. [33] [34] [35] . Interestingly, the phospho-arrays revealed that at least one member of the TAM family was activated in the majority of the melanoma cell lines, even without pervanadate treatment (Tables 1 and  2 ). Further, activation of AXL and MERTK may have some degree of mutual exclusivity, because AXL and MERTK activation rarely occurred concurrently in the melanoma cell lines.
Suppression of TYRO3 reduces melanoma cell proliferation, sensitizes cells to chemotherapeutics, decreases colony formation, and reduces tumor formation and growth (34) . Further, AXL is required for GAS6-dependent uveal melanoma cell survival (36) . In our study, knockdown of activated AXL noticeably affects cell proliferation in a primary cutaneous melanoma line (YUDOSO), 3 metastatic cutaneous lines (YUGEN8, YUSIV, YUSTE), and 2 cutaneous lines that had metastasized to the lung (YUHEF, YUTICA; Fig. 3; Supplementary Fig. S1 ). Targeting AXL in a subset of these cell lines also reduces cell migration (Fig. 3 ). It appears that this decrease in migration and proliferation correlates with a reduction in STAT3 signaling ( Fig. 3; Supplementary Fig. S1 ). Thus, AXL signaling may contribute to the constitutive activation of STAT3 that is frequently observed in human melanoma cell lines and tumors (37) .
Some of the RTKs identified by our screen (IGF1R, MET, and KIT) have been previously described in melanomas. Others, including HER3, HER4, members of the TAM family, EPHB2, and MST1R, have either not been reported as active, or are poorly characterized in this disease. These findings have therapeutic implications because some of the receptors identified in the melanoma cell lines, specifically AXL and HER3, were found in the corresponding tumor tissue (Table 3 ; Fig. 4) . Targeting AXL in a cell line that either does not express phosphorylated AXL (YUKSI) or in a cell line that does not express the receptor at all (YURIF) had little to no effect on cell behavior (Fig. 3) . Interestingly, targeting the activated receptors appears to be effective regardless of NRAS and BRAF mutation status. Both IGF1R and AXL knockdown alters cell behavior in BRAF/NRAS wild-type (WT) cells (YUHEF, YUSIV), NRAS mutant cells (YUDOSO, YUTICA), and BRAF mutant (YUGEN8, YUKSI, YULAC, YUSTE) melanoma cell lines. Although HER3 knockdown was not examined in a BRAF mutant line, it is effective in NRAS (YUDOSO) mutant and WT (YUROL) cell lines (Fig. 3) . These findings are important because expression and activation of RTKs was largely independent of mutation status, and because activation of nonmutated RTKs is a common mechanism of resistance in tumor cells attacked with RTK or pathway-directed therapeutics (38) . In fact, in a nonbiased survey of protein kinase cDNAs for the ability to promote melanoma cell resistance to the activated BRAF inhibitor PLX4720, AXL was identified as the RTK best able to rescue cell proliferation (39) . Another study identified upregulation and activation of PDGFRb receptor as a route to resistance in BRAF mutated melanoma treated with PLX4032 (40) . Perhaps coexpression of ligand-receptor conjugate pairs, as we found for several RTKs including PDGFRb, foreshadows routes to resistance.
These findings document variability in RTK expression and activation among melanomas. Identification of cancer drivers by gene mutation analysis is attractive because the technology is accurate and sensitive and because mutations in protein kinases and other signaling proteins can have strong predictive value. Nonetheless, carcinogenic alterations in RTKs and signaling pathways are also induced by changes in expression, subcellular localization, and proteolysis of ligands. Because RTKs are mainly regulated through protein-protein interactions and protein modifications, functional analyses that measure protein changes continue to provide important insights into cancer at the discovery and treatment levels. For instance, one of the early indications of anaplastic lymphoma kinase (ALK) activation in a subset of lung cancers was derived from a mass spectrometry survey of lung cancer tumors and cell lines (41) . The fact that HER3, AXL, and IGF1R knockdown was effective regardless of NRAS and BRAF status suggests that inhibition of RTKs may be valuable in combination with RAF or MEK inhibitors (Fig. 3) . The RTKs identified in this survey may provide new therapeutic opportunities for driver inhibition while improving our ability to prevent therapeutic resistance.
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